S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Roivant Sciences (ROIV) Stock Price, News & Analysis

$10.54
-0.30 (-2.77%)
(As of 03/28/2024 ET)
Today's Range
$10.37
$10.93
50-Day Range
$9.87
$11.80
52-Week Range
$6.97
$13.24
Volume
65.65 million shs
Average Volume
6.72 million shs
Market Capitalization
$8.49 billion
P/E Ratio
2.03
Dividend Yield
N/A
Price Target
$16.50

Roivant Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
56.5% Upside
$16.50 Price Target
Short Interest
Bearish
6.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Roivant Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$34.21 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($1.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

268th out of 938 stocks

Pharmaceutical Preparations Industry

120th out of 425 stocks

ROIV stock logo

About Roivant Sciences Stock (NASDAQ:ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock Price History

ROIV Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Travere Therapeutics, Inc.
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
The Analyst Landscape: 4 Takes On Roivant Sciences
Q3 2024 Roivant Sciences Ltd Earnings Call
Roivant Sciences Q3 2024 Earnings Preview
See More Headlines
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
904
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$23.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+52.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-1,009,030,000.00
Net Margins
3,624.14%
Pretax Margin
3,461.24%

Debt

Sales & Book Value

Annual Sales
$61.28 million
Book Value
$2.11 per share

Miscellaneous

Free Float
768,777,000
Market Cap
$8.71 billion
Optionable
Optionable
Beta
1.37
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Matthew Gline (Age 40)
    CEO & Director
    Comp: $1.77M
  • Dr. Eric Venker M.D. (Age 37)
    Pharm.D., President & COO
    Comp: $1.28M
  • Dr. Mayukh Sukhatme M.D. (Age 48)
    President, Chief Investment Officer & Director
    Comp: $1.72M
  • Mr. Richard Pulik (Age 45)
    Chief Financial Officer
  • Ms. Rakhi KumarMs. Rakhi Kumar (Age 44)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Josh Chen
    General Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 56)
    Head of Global Transactions & Risk Management
  • Mr. Alex Gasner
    Executive Vice President of Roivant Health

ROIV Stock Analysis - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price target for 2024?

10 analysts have issued twelve-month price objectives for Roivant Sciences' shares. Their ROIV share price targets range from $12.00 to $23.00. On average, they predict the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2024?

Roivant Sciences' stock was trading at $11.23 at the beginning of the year. Since then, ROIV stock has decreased by 6.1% and is now trading at $10.54.
View the best growth stocks for 2024 here
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our ROIV earnings forecast
.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. The firm had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a negative trailing twelve-month return on equity of 33.38% and a net margin of 3,624.14%.

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (8.63%), Rubric Capital Management LP (2.36%), Wellington Management Group LLP (1.69%), Vanguard Group Inc. (0.88%), Vanguard Group Inc. (0.88%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends
.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ROIV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners